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Abstract: Cardiac tissue engineering strategies are based
on the development of functional models of heart muscle
in vitro. Our research is focused on evaluating the feasi-
bility of different tissue engineering platforms to support
the formation of heart muscle. Our previous work was
focused on developing three-dimensional (3D) models of
heart muscle using self-organization strategies and biode-
gradable hydrogels. To build on this work, our current
study describes a third tissue engineering platform using
polymer-based scaffolding technology to engineer func-
tional heart muscle in vitro. Porous scaffolds were fabri-
cated by solubilizing chitosan in dilute glacial acetic acid,
transferring the solution to a mold, freezing the mold at
2808C followed by overnight lyophilization. The scaffolds
were rehydrated in sodium hydroxide to neutralize the
pH, sterilized in 70% ethanol and cellularized using pri-
mary cardiac myocytes. Several variables were studied:
effect of polymer concentration and chitosan solution vol-
ume (i.e., scaffold thickness) on scaffold fabrication, effect
of cell number and time in culture on active force gener-
ated by cardiomyocyte-seeded scaffolds and the effect of
lysozyme on scaffold degradation. Histology (hematoxy-
lin and eosin) and contractility (active, baseline and spe-
cific force, electrical pacing) were evaluated for the cellu-
larized constructs under different conditions. We found
that a polymer concentration in the range 1.0–2.5% (w/v)
was most suitable for scaffold fabrication while a scaffold
thickness of 200 lm was optimal for cardiac cell function-
ality. Direct injection of the cells on the scaffold did not
result in contractile constructs due to low cell retention.
Fibrin gel was required to retain the cells within the con-
structs and resulted in the formation of contractile con-
structs. We found that lower cell seeding densities, in the
range of 1–2 million cells, resulted in the formation of
contractile heart muscle, termed smart material integrated
heart muscle (SMIHMs). Chitosan concentration of 1–2%
(w/v) did not have a significant effect on the active
twitch force of SMIHMs. We found that scaffold thickness
was an important variable and only the thinnest scaffolds
evaluated (200 lm) generated any measurable active
twitch force upon electrical stimulation. The maximum
active force for SMIHMs was found to be 439.5 lN while
the maximum baseline force was found to be 2850 lN,
obtained after 11 days in culture. Histological evaluation
showed a fairly uniform cell distribution throughout the
thickness of the scaffold. We found that lysozyme concen-
tration had a profound effect on scaffold degradation
with complete scaffold degradation being achieved in 2 h
using a lysozyme concentration of 1 mg/mL. Slower deg-
radation times (in the order of weeks) were achieved by
decreasing the lysozyme concentration to 0.01 mg/mL. In
this study, we provide a detailed description for the for-
mation of contractile 3D heart muscle utilizing scaffold-
based methods. We demonstrate the effect of several vari-
ables on the formation and culture of SMIHMs.  2007
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INTRODUCTION
Tissue engineering strategies are based on the
assumption that patient-derived cells expanded in
culture maintain differentiated phenotype and can
be utilized to engineer functional three-dimensional
(3D) tissue constructs.1,2 Translating this definition
to cardiac tissue engineering necessitates the utiliza-
tion of patient-derived primary cells to re-engineer
cardiovascular structures. Although cell sourcing
remains a critical challenge for cardiac applications,
the applicability of tissue engineered heart muscle
would be far reaching. Such tissue engineering
methodology could be utilized in translating two-
dimensional monolayer cell cultures to more physio-
logical 3D tissue engineered constructs. Potential
applications for 3D tissue engineered constructs
would be in high throughput drug screening and
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clinically as patches to augment failing myocardial
function.3 There have been several models of func-
tional 3D muscle utilizing different platforms for tis-
sue engineering.4–26
Our previous work has focused on developing
functional models of cardiac muscle in vitro.27–29 Our
first tissue engineering model for cardiac muscle
was based on the self-organization of primary car-
diac myocytes on laminin-coated surfaces with
anchor points engineered at various points.27 Pri-
mary cardiac cells were plated at a high density on
tissue culture surface coated with an adhesion pro-
tein. This resulted in the formation of cohesive cell
monolayer, exhibiting a high degree of spontaneous
contractions for the duration of the culture. Contrac-
tions of the cell monolayer promote detachment
from the underlying culture surface. Subsequent
remodeling resulted in the formation of contractile
3D heart muscle, termed cardioids. The most attrac-
tive feature of the cardioid model is the formation of
3D heart muscle in the absence of any synthetic scaf-
folding material in the contractile region of the tissue
construct.
The major limiting factor in the utility of the cardi-
oid model was the extended time period required
for tissue formation; 2–3 weeks after initial cell plat-
ing. To address this concern, we evaluated the feasi-
bility of utilizing fibrin gel as a support matrix for
cardiac muscle formation.30 We found that utiliza-
tion of fibrin greatly decreased the time required for
the formation of tissue constructs to less than one
week.30 The resulting tissue constructs, termed bioen-
gineered heart muscle (BEHMs), also exhibited a
higher active force compared to cardioids. The
higher forces were likely due to the presence of
fibrin to support heart muscle formation; cardioids
may require additional interventions to promote the
formation of extracellular matrix to increase the
active force. Other groups have also shown the feasi-
bility of utilizing fibrin for cardiac tissue engineering
applications.31,32
In these previous two studies, we have demon-
strated the feasibility of using self-organization strat-
egies as well as biodegradable hydrogels to promote
the formation of contractile heart muscle in vitro. We
found the each model provided unique advantages
and critical technological challenges. As our work
progressed, we understood the need to evaluate dif-
ferent tissue engineering platforms for heart muscle.
The ‘‘dominant design’’ for heart muscle has yet to
be identified and may prove to be either one of our
platforms or contain elements from each of them; it
may very well be something totally different. To
build on our previous work, in this study, we were
interested in evaluating the feasibility of utilizing a
polymeric scaffold to support heart muscle forma-
tion in vitro. One additional motivation for this study
was to compare scaffold-based methods to our pre-
viously published models; insight can be gained by
comparing the three tissue engineering platforms
side by side.
We selected chitosan as the biomaterial for this
study because of several properties making it suita-
ble for cardiac tissue engineering applications. Chito-
san is the partially de-acetylated derivative of chitin
and consisting of b(1-4) linked D-glucosamine resi-
dues33 found in arthropod (such as crab and shrimp)
exoskeletons. The pH dependent solubility of chito-
san has provided a convenient mechanism for poly-
mer processing under mild conditions and allowed
the fabrication of porous scaffolds,34 planar mem-
branes,35 and hydrogels.36 Chitosan shares structural
homology to glycoaminoglycans and has a hydro-
philic surface,37 thereby making it suitable for spe-
cific interactions with growth factors, receptors, and
adhesion proteins.
Chitosan has fairly well-characterized degradation
kinetics.38 In vivo chitosan membranes can be
degraded by macrophages within 12 weeks while
in vitro, the degradation rate can be accelerated by
controlling enzyme concentration and can be as fast
as 4–5 days.39 The biocompatibility of chitosan has
also been the focus of several investigations40,41 and
chitosan has been shown to be nonthrombogenic,42
eliciting minimal foreign body response40 and can
safely be eliminated from the body.41
The various desirable properties of chitosan have
made it a suitable material for tissue engineering
applications and chitosan has been utilized in der-
mal,43 neural,44 cartilage,36,37 bone,45–47 vascular,
liver,48–50 pancreas,51 and cardiac52,53 tissue engineer-
ing applications. There have been no published
reports of the utility of chitosan for cardiac tissue en-
gineering applications. The purpose of this study
was to evaluate the feasibility of utilizing chitosan as
a biomaterial to support the formation of contractile
3D heart muscle in vitro.
MATERIALS AND METHODS
NIH guidelines for the care and use of laboratory ani-
mals (NIH Publication #85-23 Rev. 1985) have been
observed. All materials were purchased from Sigma (St.
Louis, MO) unless otherwise specified.
Isolation of neonatal cardiac myocytes
Cardiac myocytes were isolated from 2 to 3-day-old
F344 rat hearts using an established method.54 Hearts were
cut into fine pieces and suspended in a dissociation solu-
tion (DS) that consisted of 0.32 mg/mL collagenase type II
(Worthington Biochemical, Lakewood, NJ) and 0.6 mg/mL
pancreatin dissolved in a buffer consisting of 116 mM
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NaCl, 20 mM HEPES, 1 mM Na2HPO4, 5.5 mM glucose,
5.4 mM KCl, and 0.8 mM MgSO4. Digestion was carried
out in an orbital shaker for 5 min at 378C, after which the
supernatant was replaced with fresh DS and the digestion
process was continued for an additional 30 min. At the
end of the digestion process, the supernatant was collected
in 5 mL of horse serum (Invitrogen, Auckland, New Zea-
land), centrifuged at 1500 rpm for 5 min and the cell pellet
was resuspended in 5 mL horse serum. Fresh DS was
added to the original, undigested tissue and the digestion
process was repeated for an additional 2–3 times. Cells
from all the digests were pooled, centrifuged and then sus-
pended in culture medium consisting of 320 mL M199,
100 mL F12k, 50 mL fetal bovine serum, 25 mL horse se-
rum, 5 mL antibiotic–antimycotic (Invitrogen, Auckland,
New Zealand), hydrocortisone 40 ng/mL and insulin
100 ng/mL. No pre-plating was utilized for the primary
isolate and the cells were utilized as obtained after the iso-
lation procedure. Based on our previous experience, the
cell viability is in excess of 90%, determined 24 h after cell
plating using the MTT assay.
Fabrication of scaffolds
Chitosan scaffolds were fabricated according to a previ-
ously described method.34 Chitosan (Catalog # 4-00559,
Carbomer, San Diego, CA) was solubilized in 1% glacial
acetic acid at the desired concentration for 24 h with con-
tinuous mixing at room temperature [Fig. 1(A–C)]. The
chitosan solution was then transferred to 35-mm cell cul-
ture plates coated with polydimethylsiloxane [Fig. 1(A)]
and then frozen at 2808C for 1 h [Fig. 1(B)]. The frozen
samples were lyophilized overnight [Fig. 1(C)]. The dried
samples were carefully removed from the cell culture
plates and cut into rectangular sections 15 mm long and
5 mm wide [Fig. 1(D)]. The samples were rehydrated in
0.1M NaOH for 30 min, then samples were washed in PBS
three times and sterilized in 70% for 1 h and then stored
in PBS until use.
The chitosan concentration was varied between 0.5%
and 3.0% (w/v) with increments of 0.5%. Five scaffolds
were fabricated at each chitosan concentration by transfer-
ring 2 mL of solution into 35-mm tissue culture plates. At
each concentration, the solubility of the chitosan was eval-
uated by visually evaluating the amount of particulate ma-
terial after a 24-h mixing period. In addition, the viscosity
of the solutions at the different chitosan concentration was
noted based on the ease of solution handling and the abil-
ity to use a standard pipette for solution transfer.
The thickness of the scaffold was varied between 200
and 1000 lm with increments of 200 lm by changing the
volume of chitosan that was poured into each mold. Six
scaffolds were fabricated at each of the five thicknesses
(200, 400, 600, 800, and 1000 lm) using each of the six
chitosan concentrations (0.5%, 1.0%, 1.5%, 2.0%, 2.5%,
and 3.0%) for a total of 180 scaffolds (Table I). The thick-
ness was measured using digital calipers. Our functional
endpoint for all of these scaffolds was the ability of the
polymer solution to support the formation of 3D scaf-
Figure 1. Overview of methodology. A–D: Chitosan is poured into a mold, frozen at 2808C and lyophilized, resulting in
the formation of a porous 3D scaffold, which can be cut into any shape or size. E–H: Thrombin is added to the scaffolds,
followed by primary cardiac myocytes suspended in DMEM and fibrinogen. The scaffolds are allowed to sit in a cell cul-
ture plate for 5–10 min, followed by the addition of culture media. I: The contractile properties of the cellularized scaffolds
are evaluated by providing a pulse stimulus utilizing platinum electrodes. The force of contraction is recorded by optical
force transducers.
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folds. This was evaluated by solubility of the polymer in
1% glacial acetic acid and the macroscopic properties of
the 3D scaffold.
Degradation kinetics
We conducted a pilot study utilizing three lysozyme
(derived from chicken egg white) concentrations (1.0%,
0.1%, and 0.01% v/v in PBS) and followed the degradation
kinetics of chitosan scaffolds fabricated using a polymer
concentration of 1 and 2% at three thicknesses (200, 600,
and 1000 lm) (Table I). The degradation of the scaffolds
was followed over a 1-week time period with three time
points in between. The dry weight of the scaffold (normal-
ized to the initial scaffold weight) was used to quantify
the rate of degradation. Based on the results of these pilot
studies, we defined two degradation regimes, rapid and
slow, based on the time required for completed scaffold
degradation from hours to weeks (discussed further in the
‘‘Results’’ and ‘‘Discussion’’ sections). Rapid degradation
studies were conducted using scaffolds fabricated with
polymer concentrations of 1, 2, and 3% at thicknesses of
200, 600, and 1000 lm (Table I). Because of the fact that
complete scaffold degradation was accomplished within 2–
6 h, our data acquisition was limited to obtaining high-re-
solution digital images of the scaffolds at incremental time
points during the degradation period.
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Chitosan scaffolds were prepared using six different polymer concentrations (0.5%, 1.0%, 1.5%, 2.0%, 2.5%, and 3.0%)
and five different thicknesses (200, 400, 600, 800, and 1000 lm). Our initial evaluation was based on the ability to support
the formation of three-dimensional scaffolds. The degradation kinetics was evaluated for a subset of the scaffolds using
two different lysozyme concentrations (0.01 and 0.1 mg/mL). The change in scaffold weight was evaluated at multiple
time points during a 7-day interval. The cellularization studies were conducted for scaffolds fabricated using 1 and 2%
chitosan with a thickness of 200, 600, and 1000 lm. For each of these conditions, two cellularization methods (direct injec-
tion vs. fibrin gel) and three seeding densities (1, 2, and 5 3 106 cells/scaffolds) were evaluated at a single time point, 7
and 14 days postcellularization. The twitch force in response to electrical stimulation was evaluated for the cellularized
scaffolds. Gray bars represent conditions that were tested; n 5 3–6 for each group.
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For our second set of studies, we utilized scaffolds fabri-
cated with a polymer concentration of 1.0%, 1.5%, and
2.0% with thicknesses of 200, 400, 600, 800, and 1000 lm
and a lysozyme concentration of 0.01% (Table I). Every
scaffold was placed in an independent 35-mm tissue cul-
ture plate and 2 mL of the diluted enzyme was added to
the plate. At incremental time points, the scaffolds were
removed from the lysozyme solution, washed in PBS, air-
dried for 2 h and then weighed. As controls, PBS was
added to two groups 1.0 and 2.0% chitosan using thick-
nesses of 200 and 1000 lm. Scaffolds were weighed every
2–3 days over a 2-week period with n 5 3 for each group.
Cellularization of scaffolds
We evaluated two cellularization strategies to support
heart muscle formation: direct inject of cardiac cells and
utilization of a fibrin gel. For the first method of direct
injection, the primary cardiac cells were suspended in cul-
ture media and directly injected onto the surface of the
scaffold. A volume of 50 lL was used per scaffold and cell
concentrations of 1, 2, and 5 million cells/scaffold were
used. We utilized a 100-lL micropipette to transfer the
cells directly on to the surface of the scaffold. The cells
were allowed to settle for a period of 1 h in an incubator
and then 2 mL of culture media was added to each plate;
the scaffolds were cultured in standard 35-mm cell culture
plates with four scaffolds/plate.
For our second method using the fibrin gel, the primary
cardiac cells were suspended in culture media containing
10 U/mL of thrombin. Fibrinogen (25 lL of 20 mg/mL)
was added to each scaffold and allowed to penetrate into
the scaffolds for 15 min [Fig. 1(E)]. This suspension (25 lL)
(cardiac cells in culture media with thrombin) was added
to the scaffolds (pre-soaked in fibrinogen) [Fig. 1(F)]. An
additional 10 lL of 20 mg/mL fibrinogen was added to
each scaffold to complete the gellation process [Fig. 1(G)].
The process of gel formation continued for 15 min after
which 2 mL of culture media was added to each culture
plate. Three cell concentrations were used; 1, 2, and 5 mil-
lion cells/scaffold.
For the cellularization studies, scaffolds were fabricated
using two chitosan concentrations (1 and 2%) and three
scaffold thicknesses (200, 600, and 1000 lm) (Table I). The
twitch force of the cellularization scaffold in response to
electrical stimulation was evaluated after 7 days in culture.
Culture media consisted of 320 mL M199, 100 mL F12k,
50 mL fetal bovine serum, 25 mL horse serum and 5 mL an-
tibiotic–antimycotic (Invitrogen, Auckland, New Zealand).
A time course study was performed with a single group
of scaffolds using both cellularization methods. A chitosan
concentration of 1% was utilized with a scaffold thickness
of 200 lm. We used n 5 3 for each group and four time
points at 4, 6, 8, and 11 days postcellularization for both
methods. A total of 72 scaffolds were used for the cellula-
rization studies with 36 scaffolds used for each of the two
cellularization methods. All 72 scaffolds were used for
force testing. Based on the results of the force testing,
additional scaffolds were cellularized to evaluate the histo-
logical properties. Three scaffolds were used at each cell
concentration (1, 2, and 5 million cells/scaffold) and the
histological properties evaluated after 11 days in culture.
The scaffolds that were used for histological evaluation
were different from the scaffolds that were force tested.
Force data were obtained for all three scaffolds at the
specified time points whereas histological data were only
obtained at the terminal time point (11 days). The scaffolds
used for this study were 200 lm thick and were fabricated
using 1% chitosan solution in glacial acetic acid.
Controls for our cellularization studies were prepared
by adding fibrinogen and thrombin to the scaffolds in the
absence of any cells. The active force of the controls was
evaluated at a single time point (after 4 days in culture).
We did not evaluate the pacing characteristics, time-
dependant changes in active force and histological data for
the controls. A total of six controls were prepared.
Evaluation of contractility
The method for evaluating the contractility of tissue
engineered cardiac muscle has been described in detail.27
Briefly, the construct was placed in culture media at 378C
between parallel platinum electrodes. One end was fixed
to the plate and the other end was attached to a custom-
built optical force transducer [Fig. 1(I)]. The active twitch
force (response to a single electrical impulse) measure-
ments were then recorded at 5 V, with a frequency of
1 Hz and a 10-ms pulse width. The active twitch force was
generated in response to the contraction and relaxation of
the cells within the construct. The baseline force of the
constructs was also recorded. The baseline force was due
to the construct, in the absence of any contractions by the
cells. The magnitude of the twitch active force was used to
determine the functionality of the cellularized scaffold. The
scaffold was considered to be ‘‘functional’’ when the twitch
active force was significantly greater than noise (>3–4 lN).
The length of each construct was adjusted to obtain maxi-
mum stimulated active force using a multiaxis micromani-
pulator. This optimal length was designated as Lo and was
recorded. The cross-sectional area was calculated from the
dimensions of the construct (length 3 width 3 thickness).
The specific force (kN/m2) of the constructs was deter-
mined by normalizing the active force to the total cross-
sectional area. Initial stimulation parameters were selected
based on our previous experience with engineered cardiac
muscle constructs. The stimulation parameters had been
optimized for this system in pilot experiments. The con-
structs were electrically paced at frequencies between 1
and 7 Hz, with all other stimulation parameters remaining
constant.
Histology
Constructs were fixed in 4% paraformaldehyde for 4 h
and stored in 70% ethanol. The constructs were prepared
in an automated tissue processor (Shandon Hypercenter
XP, Thermo Electron, Waltham, MA) and then paraffin
embedded. Seven micron sections were cut and placed on
Probeon Plus slides (Fisher Scientific, Pittsburg, PA). He-
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matoxylin and eosin staining was used for morphologic
analysis of the constructs.
Scanning electron microscopy
Scanning electron microscopy (SEM) was utilized to val-
idate the pore size of the scaffolds formed in this study.
The samples were placed on a metal stub and coated with
graphite at the contacting ends. The samples were dried in
a vacuum desiccator for 6 h and then sputter-coated with
gold using a Polaron E5100 Sputter Coater. SEM was per-
formed using an AMRAY 1000-B scanning electron micro-
scope at an accelerating voltage of 3 kV. The scaffold sur-
face directly in contact with the freezing surface was uti-
lized for SEM analysis. We selected three representative
scaffolds from a single batch of lyophilized constructs for
SEM analysis; all three scaffolds were fabricated using 2%
chitosan at a thickness of 600 lm. Each scaffold was cut
into multiple sections using a razor blade and all sections
were imaged. The pore diameter was determined for
selected images using the onboard image analysis soft-
ware. We obtained representative images for all three scaf-
folds and measured the pore diameter for 3–5 pores/
image. A total of 15 pores were used to determine the
mean and standard deviation. Representative images were
selected for publication.
Statistical analysis
We used one-way ANOVAs combined with the Tukey’s
test for all pair-wise comparisons. Minitab V13.31 (State
College, PA) was used for statistical analysis.
RESULTS
Scaffold fabrication
The fabrication of chitosan scaffolds was depend-
ant on the polymer concentration and volume of
polymer solution per mold. At polymer concentra-
tions of 0.5% to 2.5%, complete solubilization of the
polymer was achieved in 1.0% glacial acetic acid af-
ter a 24-h mixing period. However, at the highest
polymer concentration test, 3.0%, un-dissolved par-
ticles were visible after mixing for 24 h in glacial
acetic acid. At the lower end, scaffolds fabricated
with 0.5% chitosan were fragile, prone to physical
damage in response to gentle handling and had a
nonuniform surface texture. Based on these observa-
tions, we selected a range of 1.0%–2.5% as our work-
ing concentration for scaffold fabrication. Scaffold
thickness was easily controlled by changing the vol-
ume of polymer solution per mold. Using 35-mm
cell culture plates and 0.5–3.0 mL of solution, we
were able to fabricate scaffolds with thicknesses of
200–1000 lm. SEM analysis showed that the average
pore diameter was 51 6 12 lm (n 5 15) (Fig. 2).
Degradation kinetics
The properties of the chitosan scaffold were affected
by varying the concentration of lysozyme, thickness
of the scaffold, and the concentration of polymer used
for scaffold fabrication (Fig. 3). Variations in polymer
thickness had no effect on the degradation time at any
Figure 2. SEM analysis of scaffolds. Images were
obtained for the surface of the scaffold which was in con-
tact with dry ice. A: Low-magnification (350) images were
obtained to show the uniform distribution of the pores. B:
Higher magnification (3200) images were obtained to
show the detailed architecture and depth of the pores. C:
Images obtained at 3800 showed that the average diame-
ter was 50 lM. The images shown are representative of
images obtained at multiple sites for three scaffolds.
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of the polymer concentrations. We were able to ac-
complish slower degradation of the scaffolds using a
lysozyme concentration of 0.1%. The rate of scaffold
degradation was the slowest using a polymer concen-
tration of 2% with a scaffold thickness of 1000 lm
[Fig. 3(A)]. Under these conditions, only 15% of the
scaffold was degraded in 48 h and 55% degraded by
day 9 [Fig. 3(A)]. The rate of scaffold degradation was
the fastest using a polymer concentration of 1% with a
scaffold thickness of 200 lm [Fig. 3(A)]. Under these
conditions, 73% of the scaffold had degraded with 48 h
and 82% degraded by day 9. At any given polymer
concentration, increasing the thickness of the scaffold
resulted in delaying the rate of degradation
[Fig. 3(B)]. The rate of degradation within the first
48 h was found to be variable. Rapid degradation
(possibly due to surface degradation) within the first
48 h was followed by a decrease during the remain-
ing time period; possibly due to substrate (chitosan)
depletion or bulk degradation. On the contrary, slow
degradation within the first 48 h was followed by a
fairly linear degradation rate; proportional to the
amount of available substrate or due to a fairly uni-
form bulk degradation [Fig. 3(A,B)]. Utilizing a lyso-
zyme concentration of 1.0%, complete degradation of
the scaffold was complete in 2–6 h, depending on
the thickness and the polymer concentration.
Scaffold cellularization
We evaluated two different methods for the cellu-
larization of scaffolds; direct injection of the cells
and utilization of a fibrin gel. Direct injection of the
cardiac cells resulted in a large number of cells out-
side the scaffolds, evaluated using an inverted
microscope showing a fairly large body of cells
directly surrounding the scaffolds. Increasing the
number of cardiac cells from 1 to 5 million per scaf-
fold resulted in a proportional increase in the num-
ber of cells observed outside the scaffold. Scaffolds
that were cellularized by direct injection did not gen-
erate any measurable twitch force upon electrical
stimulation at any of the time points tested (data not
shown). Histological evaluation of the scaffolds dem-
onstrated that only a few cells were visible through-
out the scaffolds, even at different thicknesses
throughout the scaffolds (data not shown).
Utilization of fibrin gel to support the cellulariza-
tion of the scaffolds had a profound effect on the
ability of cardiac cells to remain within the scaffolds.
Utilization of fibrin greatly reduced the number of
cells observed in proximity to the scaffolds in cul-
ture, promoted cell retention and produced con-
structs that generated active force. Macroscopical
evaluation suggested cell retention during cell cul-
ture. Histological evaluation demonstrated the pres-
ence of cells at different thicknesses of the scaffold
(Fig. 4). The presence of the chitosan scaffold was
clearly visible in the histological images as well.
Polymer concentration, scaffold thickness, and
seeding density were shown to have an effect on the
contractile properties of the cellularized scaffolds (Fig.
5). We found that only scaffolds with a thickness of
200 lm generated any measurable active twitch force
upon electrical stimulation [Fig. 5(A)]. We also found
that an initial seeding density of 1 3 106 to 2 3 106
cells per scaffold did not result in any measurable dif-
ferences in the active twitch force [Fig. 5(B)]. Similarly,
polymer concentration of 1–2 % (w/v) did not result
in any significant changes in active twitch force in
response to electrical stimulation [Fig. 5(C)].
Based on the time course study, we found that the
maximum active force was achieved after 8–11 days
in culture (Fig. 6). After 8 days in culture, the maxi-
mum active force was found to be 56.7 6 3.9 lN
(n 5 3), and 70.5 6 2.6 lN (n 5 3) after 11 days in
Figure 3. Degradation Kinetics. The effect of chitosan
concentration and scaffold thickness on the rate of degra-
dation was evaluated. A: Effect of chitosan concentration—
scaffolds were fabricated utilizing 1 and 2% chitosan. B:
Effects of chitosan thickness—scaffolds were fabricated at
different thicknesses and subjected to lysozyme degrada-
tion. For all groups, lysozyme at a concentration of 0.1%
was added to the scaffolds and the degradation kinetics
followed over time. At the specified time points, multiple
scaffolds were air-dried for 2 h and then weighed. For
each time point, n 5 4 and the error bars represent stand-
ard deviations. *Denotes a statistical difference in scaffold
weight when compared with the weight at time zero with
p < 0.5.
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culture (Fig. 6). Initial force production was low
prior, during the 6 days of culture. The active twitch
force increased after 8 days in culture and reached a
maximum at 11 days. The constructs were termed
smart material integrated heart muscle (SMIHM). For
the remainder of this article, the cellularized con-
structs will be termed SMIHMs.
Contractile behavior of SMIHMs
The maximum active force that was obtained for
SMIHMs fabricated using a polymer concentration
of 1%, a scaffold thickness of 200 lm and a plating
density of 1 million cells, was found to be 439.5 lN
with a baseline force of 2850 lN [Fig. 7(A)]. Interest-
ingly, we also observed a very high degree of spon-
taneous contractions in the SMIHMs, often lasting
for days in culture. Although high forces were rou-
tinely achievable using our cellularization methodol-
ogy, there were often batches of SMIHMs that gener-
ated considerable lower active forces, typically in the
range of 100 lN, possibly due to batch variability in
cells. Controls, generated in the absence of any cells,
did not generate any measurable force upon electri-
cal stimulation [Fig. 7(B)].
In addition to the active twitch force, we were
able to electrically pace the SMIHMs at frequencies
ranging from 1 to 7 Hz. The SMIHMs did exhibit
some degree in twitch force during electrical pacing
(Fig. 8). When paced at a frequency of 3 Hz, the
maximum active force was found to be 378.4 and
329.6 lN at a frequency of 5 Hz: the decrease in
active force was recoverable after resting (Fig. 9).
The baseline force increased in response to continu-
ous electrical pacing of SMIHMs (Fig. 9).
DISCUSSION
Our method for the fabrication of porous scaffolds
is based on the method described by Madihally and
Figure 4. Histological validation of scaffold cellularization. Serial sections were obtained for the cellularized chitosan
scaffolds after 2 weeks in culture. A seeding density of 2 million cells per scaffold was used. Scaffolds were fabricated
using 1% chitosan in glacial acetic acid. The scaffolds were 200 lm thick. Sections were obtained at 10 lM increments.
Slides were stained with hematoxylin and eosin. A: Top surface—refers to the surface on which the cardiac cells were
added. A very large number of cells can be observed to be uniformly distributed throughout the scaffold. B: Middle sur-
face—at the center of the scaffold, the number of cells is lower than the number of cells on the top surface. However, there
appears to be a fairly large number of cells still present at the center of the scaffold. The cells do appear to be fairly uni-
formly distributed throughout the scaffold. C: Bottom surface—the distribution of the cells was similar to the distribution
of the cells at the center of the scaffold. In all cases, the scaffold stains a distinctive pink color making it fairly easy to
identify. In addition, we observed that the fiber orientation and pore distribution was distorted in most of the slides used
for histological evaluation. This was very likely a result of the sectioning of the slides using a cryostat. [Color figure can
be viewed in the online issue, which is available at www.interscience.wiley.com.]
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Matthew.34 Using this method, chitosan polymer is
solubilized in dilute glacial acetic acid, frozen and
lyophilized to remove water crystals, resulting in
pore formation. There are several variables that can
be manipulated to optimize material properties for
specific applications. The size of the pores is deter-
mined by the size of the water crystals, which in
turn is dependant on the freezing temperature; a
lower temperature results in small water crystals
and a smaller pore size, as shown by Madihally and
Matthew.34 Based on previously published work by
Madihally and Matthew,34 we selected a specific
pore size of 50 lm and a freezing temperature of
2808C as this has been shown to be the average
pore diameter of neonatal cardiac myocytes.55 The
pore diameter was validated utilizing scanning elec-
tron micrographs. We optimized the polymer con-
centration and the scaffold thickness for our applica-
tions. We determined that the lowest polymer con-
centration (0.5%) resulted in the formation of fragile
scaffolds while the highest polymer concentration
(3.0%) was not completely solubilized in acid. Our
working range for polymer concentration was
selected as 1.0%–2.5%. We have not seen any other
published studies looking at the polymer concentra-
tion, although it is likely that the specific range
would vary based on application and vary depend-
ing on processing conditions. Scaffold thickness was
found to be an important variable for cardiac appli-
cations. Fairly thick scaffolds, in excess of 600 lm
did not support the formation of contractile heart
muscle, possibly due to nutrient deprivation of the
cardiac cells. On the contrary, the thinnest scaffold
we tested (200 lm) proved to be the most suitable to
support heart muscle formation. It is interesting to
Figure 5. Effect of seeding density and polymer concen-
tration. A: Parameter optimization—Three seeding den-
sities (1, 2, and 5 3 106 cells/scaffold), three scaffold thick-
nesses (200, 600, and 1000 lm), and two polymer concen-
trations (1 and 2%, w/v) were utilized for scaffold
cellularization using fibrin gel as a support matrix. The
active twitch force was evaluated 7 days after cellulariza-
tion. Scaffolds cellularization using low-seeding densities
(1 and 2 3 106) at the lowest scaffold thickness (200 lm)
generated measurable active twitch force for both polymer
concentrations tested (1 and 2%, w/v). B: Effect of cell
number—There was no significant difference between the
active twitch forces of scaffolds cellularized with 1 3 106
or 2 3 106 cells per scaffold. The scaffolds were fabricated
utilizing 1% chitosan and a thickness of 200 lm. C: Effect
of polymer concentration—There was no significant differ-
ence between the active twitch forces of cellularized scaf-
folds using either 1 or 2% chitosan. A seeding density of
1 3 106 cells per scaffold were used and a scaffold thick-
ness of 200 lm.
Figure 6. Changes in twitch force of cellularized scaffolds
over Time. The average twitch of the constructs was eval-
uated at 4, 6, 8, and 11 days after cellularization. A total of
three constructs were utilized for this study and five
twitches obtained for each construct at every time point.
The plot shows the average values and the error bars rep-
resent SEM. *Denotes a significant difference in the aver-
age twitch force with p < 0.05. A polymer concentration of
1% and a scaffold thickness of 200 lm was utilized with a
plating density of 1 million cells.
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note that the scaffold thickness corresponds very
well to the diffusion limit of oxygen in vitro, which
has also be determined to be in the vicinity of
200 lm.56 We did not actually correlate the scaffold
thickness to cell/construct viability, but rather
empirically (based on twitch force) determined the
working range for our applications. In concluding
our discussion on material processing, we believe
that our pilot studies helped us to define conditions
that are most suited for our applications.
We evaluated the changes in scaffold performance
by measuring the active force of constructs cellular-
ized at different seeding densities; 1, 2, and 5 million
cells per construct. This range was selected based on
our findings with BEHM, utilizing fibrin gel. We
found that very low cell numbers (less than 1 million
cells/construct) and very high cell numbers (greater
than 4 million cells/BEHM) produced fairly low
active forces. BEHMs formed using the lower cell
numbers did not have adequate contractile proteins,
while BEHMs formed with higher cell numbers suf-
fered nutrient deprivation. Our results with SMIHMs
followed the same pattern. Very high seeding den-
sities (12 million cells/SMIHM, data not shown)
resulted in rapid scaffold degradation and presented
a challenge to physically transfer such a large num-
ber of cells in a small volume of media, typically
50 lL required for construct cellularization. Our
results for the lower cell numbers, 1–5 million, pro-
duced the best results, consistent with our findings
in other tissue models that we have developed. The
higher seeding densities (5 million cells/SMIHM)
did not generate measurable force and was consist-
ent with our findings in the BEHM model.
Our longevity studies showed that the active force
of the SMIHMs gradually increased over a time
Figure 7. Representative twitch force tracing for the cellu-
larized scaffolds. The constructs were electrically stimu-
lated between parallel platinum electrodes. The stimula-
tion parameters used were 10 V bipolar impulse with a
pulse width of 10 ms. The twitch force was recorded by
attaching one end of the construct to the arm of an opti-
cal force transducer. A: Cellularized construct—The base-
line force was found to be 2850 lN and the maximum
twitch force was found to be 439.5 lN. B: Controls—In
the absence of cardiac cells, the scaffolds did not generate
any measurable twitch force upon electrical stimulation.
The baseline force was found to be 1014.3 lN. ES, electri-
cal stimulus; TF, twitch force. Single arrows point to the
spontaneous contractions of the construct. For both cases,
a polymer concentration of 1% and a scaffold thickness of
200 lm was utilized with a plating density of 1 million
cells.
Figure 8. Electrical pacing of cellularized constructs. The
constructs were electrically stimulated between parallel
platinum electrodes using a voltage of 10 V, pulse width
of 10 ms and frequencies of (A) 3 Hz and (B) 5 Hz. The
baseline force for the constructs being paced at 3 Hz was
found to be 1300 lN and the maximum twitch force was
found to be 378.4 lN, a polymer concentration of 1% and
a scaffold thickness of 200 lm was utilized with a plating
density of 1 million cells.
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period of 8–11 days and then started to decrease.
The increase in active force is indicative of functional
tissue remodeling and does provide some indirect
measure of the ability of the scaffolding model to
support the phenotypic maturation of primary car-
diac cells. Detailed histological and biochemical
characterizations would be required to determine the
degree of tissue formation of the SMIHMs. The lim-
ited longevity beyond tissue maturation is somewhat
troubling at this stage as we have not been able to
maintain the active force of the SMIHMs beyond 2
weeks in culture. Optimization of the scaffold fabri-
cation, cellularization methods, and culture condi-
tions as well as development of micro-perfusion sys-
tems would be required to promote longevity of the
SMIHMs in culture.
The ability to control the degradation kinetics of
the chitosan scaffold is important. As tissue develop-
ment and maturation takes place, the rate of scaffold
degradation would need to be balanced with the
rate of new tissue formation, necessitating accurate
regulation of the degradation kinetics. Our results
show that the rate of degradation of chitosan scaf-
folds can be modulated to promote complete scaf-
fold degradation in time frames as short as 2 h. The
kinetics can also be regulated to promote slower
degradation of the scaffold, often in the order of
weeks.
The degradation kinetics of chitosan films have
been reported by other groups. Lee fabricated thin
films of chitosan (thickness of 40–60 lm, dimension
of 10 3 10 mm2)42 and used lysozyme (1 mg/mL)
to evaluate the degradation kinetics. It was shown
that 20% of the film was degraded after 48 h. In
another study, Tomihata and Ikada39 fabricated chi-
tosan films (thickness 150 lm) using varying
degrees of de-acylation. After 50 h of lysozyme
degradation (4 mg/mL), 50% of the film was
degraded with a degree of de-acylation of 69% and
only 10% degradation was achieved with a degree
of de-acylation of 90%. Although the conditions
described in these studies are not identical to the
conditions in our study, the results are fairly com-
parable and show some general themes about the
degradation of chitosan scaffolds/films. First, utili-
zation of lysozyme is a fairly easy and effective
method of promoting the degradation of chitosan
scaffolds.37 Second, there are several variables that
can be manipulated to modulate the degradation
kinetics; these include the degree of de-acylation
and substitution of the acetyl group with other side
agents. Third, as we have shown in this study, the
polymer percentage, the thickness of the scaffold
and the concentration of the enzyme can have a
profound effect on the degradation kinetics of the
chitosan scaffolds.
The ability to carefully modulate the degradation
kinetics of chitosan scaffolds would be useful for
several potential applications in cardiac tissue engi-
neering. First, the rate of scaffold degradation can be
balanced to match the rate of new tissue formation
by the primary cardiac cells. This is particularly
interesting, permitting the formation of completely
cellularized constructs in the absence of any syn-
thetic scaffolding material prior to implantation; this
can be accomplished by balancing the rate of colla-
gen synthesis by the rate of scaffold degradation.
This particular feature is our reasoning for terming
the scaffolds as ‘‘smart materials". Second, cardio-
active factors can be covalently linked to the chitosan
polymer, permitting controlled release to allow phe-
notypic modulation of the cardiac cells during tissue
formation.57,58
Figure 9. Effect of electrical pacing on the twitch force
and baseline force. A: Twitch force—There was a decrease
in the twitch force of the constructs when electrically
paced at frequencies of 1–7 Hz in succession. The twitch
force decreased from a value of 390.6 lN at 1 Hz to a
value of 183.1 lN at 7 Hz. However, the twitch force was
restored to a value of 378.4 lN after the constructs were
allowed to rest for 10 min and then electrically paced at
1 Hz. B: Baseline force—There was an increase in the base-
line force with each pacing frequency tested, including a
pacing frequency of 1 Hz after a 10-min rest period. The
baseline force increased from a value of 1177.8 lN at 1 Hz
to a value of 1458.6lN at 7 Hz. This study was conducted
for three constructs and the data shown were obtained
from a single construct and is representative of the group.
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We evaluated two methods for scaffold cellulariza-
tion with different functional outcomes. The first
method was a simple strategy, involving direct injec-
tion of the primary cardiac cells on the surface of the
scaffold. This method did not result in constructs
that generated any measurable force upon electrical
stimulation. Utilization of a fibrin gel had a positive
effect on the functional performance of the con-
structs. There are several interesting points to con-
sider regarding this study. Firstly, chitosan is a com-
mercially available ‘‘off-the-shelf’’ polymer that we
evaluated to support cardiac cell remodeling. The
inability of the chitosan to support cardiac cell
attachment directly after cell injection demonstrates
the lack of functional interaction points with chito-
san. This means that the cardiac cells may not be
forming a physiological bond with the chitosan, pos-
sibly due to the lack of integrin-binding sites. It
would be necessary to engineer bio-mimetic activity
within the polymer backbone of chitosan to promote
functional interaction with primary cardiac cells.
Several studies have shown that this is a feasible
option as chitosan has multiple functional sites,
amine and hydroxyl, which can be covalently linked
to bioactive factors. Moreover, the inability of the
cardiac cells to functionally interact with chitosan
demonstrates the need to develop novel biomaterials
specifically targeted for cardiac tissue engineering
applications, a reoccurring theme in the field of func-
tional tissue engineering.59,60
To overcome some of the difficulties in working
with chitosan, we sought to use fibrin as a support
matrix during construct formation. The utilization of
fibrin resulted in the formation of 3D tissue engi-
neered constructs. The incorporation of fibrin into
our scaffold-based model does lead to an interesting
dimension. The degradation kinetics of the fibrin can
be manipulated, independent of the degradation of
the chitosan.
There has only been one other group utilizing pol-
ymeric scaffolds to engineer functional heart muscle.
Freed and coworkers utilize polyglycolic acid (PGA)
as the scaffolding materials with direct cell injection
being utilized for cellularization.24,25 Although a
high degree of cellularization has been demon-
strated, contractile performance has not been
reported.24,25,61 The work by this group clearly dem-
onstrates that biomaterials can be cellularized in the
absence of carriers, like fibrin. Although PGA has
been shown to support functional remodeling of pri-
mary cardiac cells, chitosan lacks this functionality
in its commercially available unmodified form. As
more biomaterials are evaluated for cardiac tissue
engineering applications, each material will need to
be developed based on its specific properties; it
would be difficult to make generalizations about the
suitability of any biomaterial to support cardiac cell
remodeling. Biomaterials would need to be eval-
uated on a case-by-case basis and process to meet
the needs of specific applications.
SMIHMs generated active force upon electrical
stimulation. The maximum twitch force was found
to be 439.5 lN with a specific force of 0.44 kN/m2.
Our previous two models of heart muscle tissue
in vitro, cardioids,27 and BEHMs,30 have shown to
generate considerably higher specific forces than the
current model. Cardioids generate an average spe-
cific force of 2–4 kN/m2 while the specific force of
BEHMs has been shown to be as high as 12–15 kN/
m2.27,30 The twitch force of cardioids is in the range
of 200–300 lN and 600–800 lN for BEHMs and the
cross-sectional area of both cardioids and BEHMs in
the range of 200–300 lm.
The specific force of the SMIHMs is significantly
lower than the specific force for our other two mod-
els. This could be due to the fact that that chitosan is
not functionally interacting with the primary cardiac
cells. Our speculation is based on the inability of the
cellularized chitosan scaffold to generate measurable
forces in the absence of fibrin gel. The more likely
scenario at this stage is that the scaffold is serving as
a nonfunctional carrier of the cardiac myocytes.
Modification of the material, possibly by fabricating
scaffolds with collagen or covalently linking adhe-
sion peptides, may provide increased functionality.
Eschenhagen and coworkers15 developed a model
of 3D heart muscle using collagen gel as the support
matrix and the resulting heart muscle shows fairly
high contractile forces. The work compares well with
our BEHM model in terms of contractile perform-
ance, while the contractile forces of our current
model are considerably lower. The similarity
between our BEHM model and the work by Eschen-
hagen and coworkers is in the utilization of biode-
gradable hydrogels to support the formation of func-
tional tissue engineered heart muscle; we utilized
fibrin while Eschenhagen used collagen type I.
Hydrogels, in general have been shown to support
heart muscle formation; at least based on current
technology.
Okanos and coworkers’ model22 compares well
with our cardioid model; both based on the self-or-
ganization of primary cardiac cells. The similarity is
mainly methodological, whereby functional 3D heart
muscle constructs are generated in the absence of
scaffolding material. Okano and coworkers utilized
temperature-sensitive polymers to promote the
detachment of a cohesive monolayer of cardiac cells
while we utilized surface concentration of adhesion
proteins for monolayer delamination.
Freeds and coworkers utilized PGA to support the
formation of heart muscle and have shown several
physiological performance metrics in terms of histo-
logical and biochemical characterization.25 Our
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model seems to compare well with the model pub-
lished by Freeds and coworkers in terms of demon-
strating the ability of polymeric scaffolds to support
the functional remodeling of primary cells. The simi-
larity between our SMIHM model and the work by
Freed and coworkers is the utilization of polymeric
scaffold followed by cellularization with primary
cardiac cells.
In addition to evaluating the active force, we eval-
uated the baseline force and the pacing characteris-
tics of the SMIHMs. The baseline force of the
SMHIMs were considerably higher than the baseline
force for cardioids27 and BEHMs.30 This was some-
what expected due to the rigidity of the chitosan
scaffold and its ability to generate baseline tension,
even in an un-stimulated state. More interesting was
the increase in baseline force in response to electrical
stimulation. This was particularly evident in the
studies with variations in the pacing frequency;
increasing the pacing frequency resulted in an
increase in the baseline force. We also observed a
decrease in the active force of the SMHIMs in
response to increased electrical pacing. Recovery of
force after a period of rest indicated that the muscle
cells did not undergo physical damage during the
electrical stimulations and induced contractions.
The authors thank Dr. M. Welsh, Associate Chair of the
Department of Molecular and Cell Biology at the Univer-
sity of Michigan for donating a lyophilizer that was uti-
lized extensively in this project.
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